Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232670 | 0.88 | MAPK1 (0.48) | NAMPTMAPTL3MBTL1CA12CA1 | |
| SCHEMBL25365161 | 0.85 | KLKB1 (0.44) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL12513988 | 0.85 | NAMPT (0.43) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL19971719 | 0.83 | L3MBTL1 (0.44) | NAMPTMAPTL3MBTL1CA12CA1 | |
| SCHEMBL24307053 | 0.83 | L3MBTL1 (0.44) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL21682662 | 0.82 | CA12 (0.45) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL13707719 | 0.82 | L3MBTL1 (0.43) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL22828360 | 0.82 | TRPA1 (0.50) | NAMPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL17680512 | 0.82 | L3MBTL1 (0.43) | NAMPTMAPTL3MBTL1CA12CA1 | |
| SCHEMBL16282482 | 0.82 | GRM2 (0.45) | NAMPTL3MBTL1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118612-A1 | TARGETING COMPOUNDS | ZAFGEN, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | disclosed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| EP-1294698-A1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000626-A1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2002-01-03 | — | — | WO | disclosed |
| EP-1115731-A2 | NOVEL PYRANOSES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-07-18 | — | — | EP | disclosed |
| EP-0656348-B1 | Aceric acid derivatives as medicaments | HOFFMANN LA ROCHE (CH) | 2000-05-03 | — | — | EP | disclosed |
| WO-2000014097-A2 | NOVEL PYRANOSES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-16 | — | — | WO | disclosed |
| US-5973188-A | Acetic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5726185-A | BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELET AGGREGATION AND CELL TO CELL ADHESION | HOFFMANN-LA ROCHE INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0656348-A2 | Aceric acid derivatives as medicaments | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | NAMPT 1917/4885MAPT 2234/4885L3MBTL1 4439/4885 |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | AVPR2, AVPR1A, AVPR1B | NAMPT 4620/4885MAPT 4646/4885L3MBTL1 4869/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | NAMPT 2492/4885MAPT 1950/4885L3MBTL1 3320/4885 |
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | NAMPT 1855/4885MAPT 1278/4885L3MBTL1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.